Search company, investor...

Opal Therapeutics


Series A | Alive

Total Raised


Last Raised

$6M | 18 yrs ago

About Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

Headquarters Location

Melbourne, Victoria,


Missing: Opal Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Opal Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Opal Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Opal Therapeutics is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Opal Therapeutics News

OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C. - GBS Venture Partners

Jun 27, 2013

OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C. 19 / 12 / 2005 Opal Therapeutics Inc., an immunotherapy development company targeting HIV and Hepatitis C, raises $6 million Series A financing. The company raised the funds from an international syndicate led by GBS Venture Partners, Melbourne, Australia. Other members of the syndicate are Alloy Ventures, Alta Partners, and Uniseed. OPAL is an immunotherapy development company focusing on novel therapies for HIV and Hepatitis C (HCV) based on a proprietary technology from the University of Melbourne. The company is incorporated in Delaware with preclinical operations in Australia and California. HIV and HCV are chronic viral infections inadequately treated by current therapies. Cellular immunity has an important role in the progression of both diseases, however, current treatments have generally failed to induce strong cellular immune responses. OPAL has developed a unique approach to generate high levels of cellular immune responses for the treatment of chronic infection. The Series A funding will be used initially to extend the company's intellectual property, hire staff, and manufacture the preclinical materials. It will support preclinical safety and efficacy studies and phase I human clinical trials in HIV. The founding scientist, Dr Stephen Kent, at the University of Melbourne, is a thought leader in HIV immunology. Dr Kent said his team have developed the novel treatment with outstanding effectiveness in generating strong cellular responses in extensive in vivo laboratory studies in animal models. "This funding will be used initially to refine the OPAL technology through final preclinical development and into clinical trials in humans. " Kent said. "This is a very exciting day for us. OPAL will develop a technology with the potential to provide a new treatment for a very large population of people with HIV and HCV. " Kent said. "In HIV the OPAL technology is intended to complement existing therapies and allow patients to live longer with fewer side effects and generate less drug resistance. In HCV the OPAL technology is intended to complement existing therapies and has the potential to provide an effective treatment for the large group of patients who do not respond to current therapies. " OPAL uses short peptides from the target virus to generate a strong immune response so patients can improve control of the infection. The peptides are mixed ex vivo (outside the body) with blood where they bind to immune cells and are then distributed to all parts of the body to stimulate the immune response. Kent said "It has long been known cellular immune responses have the potential to change the course of an infection. OPAL's new products have the potential to achieve what other therapies generally fail to do - and that is to generate significant cellular immunity and control viremia. "  

Opal Therapeutics Frequently Asked Questions (FAQ)

  • Where is Opal Therapeutics's headquarters?

    Opal Therapeutics's headquarters is located at Melbourne.

  • What is Opal Therapeutics's latest funding round?

    Opal Therapeutics's latest funding round is Series A.

  • How much did Opal Therapeutics raise?

    Opal Therapeutics raised a total of $6M.

  • Who are the investors of Opal Therapeutics?

    Investors of Opal Therapeutics include Alloy Ventures, Alta Partners, GBS Venture Partners, UniSeed and University of Melbourne.

  • Who are Opal Therapeutics's competitors?

    Competitors of Opal Therapeutics include Intarcia Therapeutics, CoImmune, Profectus BioSciences, Okairos, Aldagen and 12 more.

Compare Opal Therapeutics to Competitors

Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.


MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada.

Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.


Apath is a pharmaceutical discovery and development company with a focus on the hepatitis C virus ("HCV") and other human viral pathogens. Apath was founded by Charles M. Rice, Ph.D., currently Professor of Molecular Microbiology, Rockefeller University and formerly of the Washington University (St. Louis) School of Medicine. Apath is engaged in the commercial application of virology and viral genetics to discover and develop a broad range of diagnostic and therapeutic products for viral infections, and for applications using viruses as vectors. Apath's primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses such as influenza, respiratory syncytial virus ("RSV"), and hemorrhagic fever viruses (e.g., Ebola).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.